HIV Malignancy Specimens for Research at No Charge
On behalf of Toby T. Hecht, Ph.D. Associate Director, Translational Research Program, DCTD, NCI and Robert Yarchoan, M.D., Director, Office of HIV and AIDS Malignancy, NCI To the HIV Malignancy …
Favorable research results from the PURPOSE 1 trial (South Africa and Uganda) have been published in the New England Journal of Medicine and presented at IAS 2024 in Munich, use …
Have you heard? The National Institutes of Health (NIH) is revising the application and review criteria for fellowship applications, beginning with those submitted January 25, 2025 forward. Fellowship training awards …
Through this Notice of Special Interest (NOSI), NOT-CA-23-070 the National Cancer Institute (NCI) is a continuation of NOT-CA-20-022, “High” or “Medium” Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers, which expired …
Discovery from researchers at Dana Farber Cancer Center and collaborators opens the way to drugs that can prevent T-cell therapies from losing their potency over time. Read more about the …
The ACSR is proud to celebrate Arti Vashist, Fall 2021 YIPA recipient! Dr. Vashist will be presenting her poster abstract entitled: “Development of vegetable oil-based Micro/nanogels as versatile system for …
(From the CFAR Adelante RFA: https://cfar-adelante.org/wp-content/uploads/2022/08/Adelante.RFA-CohortV_FINAL-081522.pdf) As confirmed by the National Ending the HIV Epidemic in the U.S. (EHE) Initiative, there has been adearth of culturally responsive research specific to …
Use of stem cells for research has not be conducted without its share of controversy. New research using a new transplant method involving umbilical cord blood, presented at this year’s …
How do HIV/AIDS & cancer research continue to converge? Read more about the early results from a novel study which shows that pembrolizumab, a cancer drug, can flush HIV from …